| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA) announced today that the Company will present preclinical
data on RDEA594, its lead product candidate for the treatment of gout, as
well as preclinical data on RDEA119,its lead mitogen-activated ERK kinase
(MEK) inhibitor for the treatment of inflammation associated with gouty
arthritis, at the 2008 American College of American College of Rheumatology
(ACR) / Association of Rheumatology Health Professionals (ARHP) Annual
Scientific Meeting in San Francisco, California.
Presentation Details are as Follows:
Date/Time: Sunday, October 26, 2008, 9:00 a.m. - 11:00 a.m. PDT
Abstract Title: RDEA594, A Potential Uric Acid Lowering Agent through
Inhibition of Uric Acid Reuptake, Shows Better
Pharmakokinetics than its Prodrug RDEA806
Abstract Number: 28
Session Name: Crystal Associated Arthropathies
Location: Hall A, Poster Board 28
Date/Time: Tuesday, October 28, 2008, 2:45 p.m. - 3:00 p.m. PDT
Abstract Title: MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine
Production Induced by Monosodium Urate Crystals
Abstract Number: 1942
Session Name: Crystal Associated Arthropathies
Location: Room 104
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, gout, cancer and inflammatory
diseases. We have five product candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product candidate
is RDEA806, a non-nucleoside revers
'/>"/>
| SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |